На этой странице перечислены больницы направления «Гинекология» (включая Contraceptive Implant) в Мумбаи, Индия, включая Nanavati Super Specialty Hospital, Kokilaben Dhirubhai Ambani Hospital, Tata Memorial Hospital, Apollo Hospitals, Navi Mumbai и другие.
Спросите нас о «Contraceptive Implant» в Мумбаи, Индия
Оставьте свои данные — наша команда координации свяжется с вами и расскажет о следующих шагах.
Сравните 17 аккредитованных больниц (Гинекология) в Мумбаи, Индия
Рекомендуем🇮🇳 Nanavati Super Specialty Hospital
Больница занимает 1-е место в этом списке по указанному рейтингу (5/5, 12 отзывов).
🇮🇳 Kokilaben Dhirubhai Ambani Hospital
Больница занимает 2-е место в этом списке по указанному рейтингу (4.8/5, 1800 отзывов).
🇮🇳 Tata Memorial Hospital
Больница занимает 3-е место в этом списке по указанному рейтингу (4.8/5, 2500 отзывов).
🇮🇳 Apollo Hospitals, Navi Mumbai
Больница занимает 4-е место в этом списке по указанному рейтингу (4.8/5, 512 отзывов).
🇮🇳 Gleneagles Hospital, Mumbai
Больница занимает 5-е место в этом списке по указанному рейтингу (4.8/5, 615 отзывов).
🇮🇳 Lilavati Hospital And Research Centre
Больница занимает 6-е место в этом списке по указанному рейтингу (4.8/5, 724 отзывов).
🇮🇳 Jaslok Hospital
Больница занимает 7-е место в этом списке по указанному рейтингу (4.6/5, 129 отзывов).
🇮🇳 Gleneagles Global Hospitals (Global Hospitals)
Больница занимает 8-е место в этом списке по указанному рейтингу (4.6/5, 183 отзывов).
🇮🇳 Medicover Hospital, Navi Mumbai
Больница занимает 9-е место в этом списке по указанному рейтингу (4.6/5, 143 отзывов).
🇮🇳 KIMS Hospitals, Thane
Больница занимает 10-е место в этом списке по указанному рейтингу (4.6/5, 58 отзывов).
🇮🇳 Fortis Hospital, Mulund
Больница занимает 11-е место в этом списке по указанному рейтингу (4.5/5, 79 отзывов).
🇮🇳 Fortis Hiranandani Hospital, Vashi
Больница занимает 12-е место в этом списке по указанному рейтингу (4.5/5, 83 отзывов).
🇮🇳 Wockhardt Hospital
Больница занимает 13-е место в этом списке по указанному рейтингу (4.4/5, 30 отзывов).
🇮🇳 Wockhardt Super Speciality Hospital
Больница занимает 14-е место в этом списке по указанному рейтингу (4.4/5, 48 отзывов).
🇮🇳 S. L. Raheja Hospital
Больница занимает 15-е место в этом списке по указанному рейтингу (4.4/5, 121 отзывов).
🇮🇳 Saifee Hospital
Больница занимает 16-е место в этом списке по указанному рейтингу (4.3/5, 97 отзывов).
🇮🇳 Dr. L H Hiranandani Hospital
Больница занимает 17-е место в этом списке по указанному рейтингу (4.3/5, 141 отзывов).
Как мы выбираем эти больницы
Больница появляется на этой странице, если направление «Гинекология» указано среди её специализаций и она находится в Мумбаи, Индия. Сортировка — по указанному рейтингу (по убыванию), без редакционного рейтинга «лучших».
Как выбрать лучшую больницу для «contraceptive implant» в Мумбаи, Индия?
Выбор подходящей больницы для «contraceptive implant» — важное решение в вашем пути лечения. Вот на что стоит обратить внимание:
Международная аккредитация
Ищите больницу с международной аккредитацией, например JCI или NABH — см. отметки аккредитации у каждой больницы ниже.
Специализация
Убедитесь, что в больнице есть отделение, специализирующееся на «Гинекология», а не только общая помощь.
Мощность и опыт
Количество коек и год основания, указанные ниже, отражают масштаб и операционный опыт больницы.
Прозрачность стоимости
Запросите детализированную смету перед поездкой — используйте наш калькулятор стоимости для первичной оценки.
Что нужно знать о процедуре «Contraceptive Implant»
The contraceptive implant (Nexplanon/Implanon NXT) is a highly effective, long-acting reversible contraceptive (LARC) — a small, flexible etonogestrel-releasing rod inserted subdermally into the upper arm, delivering over 99% efficacy for up to 3 years with a single 60–90 second in-office procedure. International patients choose India and the UAE through GAF Healthcare for access to experienced gynaecologists, ultrasound-guided precision insertion protocols, rapid same-day procedures, and costs that are a fraction of what they would pay in the UK, US, or Europe. GAF Healthcare's end-to-end coordination — spanning pre-travel consultation, accredited hospital or clinic placement, and post-insertion follow-up — ensures a seamless, medically supervised experience for women travelling from across the Middle East, Africa, Europe, and beyond. Hospital Stay: 0 days (outpatient day procedure; no overnight admission required) • Total Stay in Country (Fit-to-Fly): Same day to 2 days (most patients fly home within 24–48 hours of insertion; no physiological restriction on air travel post-procedure) • Success Rate: Greater than 99% (Pearl Index < 0.1 per 100 woman-years; among the most effective contraceptive methods available)
Clinical Overview
The subdermal contraceptive implant is a single-rod, non-biodegradable device measuring 40 mm × 2 mm, pre-loaded with 68 mg of etonogestrel (ENG) — the active metabolite of desogestrel — embedded in an ethylene vinyl acetate (EVA) copolymer matrix. After insertion into the medial aspect of the non-dominant upper arm, the rod releases ENG at an initial rate of approximately 60–70 µg/day, declining to roughly 25–30 µg/day by year three. The primary contraceptive mechanism is robust suppression of the LH surge and ovulation; secondary mechanisms include cervical mucus thickening (reducing sperm penetration) and endometrial atrophy. Serum ENG levels reach contraceptive threshold within 8 hours of insertion, providing immediate protection when inserted within the first five days of the menstrual cycle. From a physiological standpoint, the implant avoids the hepatic first-pass metabolism associated with combined oral contraceptives, making it particularly suitable for women with hepatic conditions, migraines with aura, hypertension, or thromboembolic risk factors in whom oestrogen-containing methods are contraindicated. Unlike depot medroxyprogesterone acetate (DMPA/Depo-Provera), return to fertility after removal is rapid — median time to ovulation resumption is 21 days — making it an excellent choice for women who may wish to conceive in the near future. The global standard of care for implant insertion now mandates real-time ultrasound-guided or radio-opaque (Nexplanon) device placement to prevent deep muscular insertion into the biceps or neurovascular bundle, which is the leading cause of difficult removal. In accredited facilities across India and the UAE, trained gynaecologists use the applicator-based, single-handed insertion technique with the patient's arm in the 90°/120° abducted and externally rotated position, followed by tactile and visual confirmation, and — increasingly — ultrasound verification in complex cases or patients with high BMI.
Who is a Candidate?
• ELIGIBLE CANDIDATES: • Women seeking highly effective (>99%), long-acting, reversible contraception for up to 3 years • Women in whom oestrogen-containing contraceptives (combined oral pills, patch, ring, combined injectable) are contraindicated — including those with migraine with aura, personal or family history of VTE, hypertension, liver disease, or cardiovascular risk factors (WHO MEC Category 3/4 for oestrogen) • Breastfeeding mothers (ENG implant is WHO MEC Category 1 from 6 weeks postpartum; progestogen-only, does not affect milk supply) • Postpartum women (can be inserted immediately postpartum — within 24 hours of delivery — or at any time if pregnancy is reliably excluded) • Post-abortion insertion (immediate, same-day insertion recommended by FSRH/WHO to prevent repeat unintended pregnancy) • Women with medical conditions benefiting from menstrual suppression (endometriosis, dysmenorrhoea, iron-deficiency anaemia secondary to heavy menstrual bleeding) • Women who desire a 'fit-and-forget' method without daily, weekly, or monthly compliance demands • Adolescents and young women (no age lower limit; suitable from menarche) • Women with sickle cell disease (progestogen-only methods are WHO MEC Category 1) • REQUIRED PRE-PROCEDURE ASSESSMENTS: • Comprehensive medical and sexual history to assign WHO Medical Eligibility Criteria (MEC) category • Urine or serum beta-hCG pregnancy test (mandatory on day of insertion to exclude pregnancy) • Blood pressure measurement • STI/cervical swab screening if clinically indicated (especially in women with PID history) • Pelvic examination if clinically warranted • Ultrasound (not routinely required for standard insertion, but recommended for women with BMI > 30 kg/m² or needle phobia to plan insertion depth and verify placement post-insertion) • Coagulation screen and liver function tests if hepatic disease is suspected • ABSOLUTE CONTRAINDICATIONS (WHO MEC Category 4): • Current or past breast cancer (hormone-sensitive malignancy) • Severe decompensated cirrhosis • Hepatocellular adenoma or malignant liver tumour • Unexplained abnormal vaginal bleeding under investigation (relative — defer until diagnosis confirmed) • Known or suspected pregnancy • Hypersensitivity to etonogestrel, EVA matrix components, or barium sulphate (Nexplanon radio-opaque marker) • RELATIVE CONTRAINDICATIONS / SPECIAL POPULATIONS (WHO MEC Category 2–3): • Women on enzyme-inducing medications (rifampicin, carbamazepine, phenytoin, St John's Wort) — efficacy may be reduced; concomitant barrier contraception or alternative LARC (IUD) recommended • Current venous thromboembolism on anticoagulation (Category 2 — benefits generally outweigh risks) • History of functional ovarian cysts • Severe depression (monitor; progestogens may affect mood in susceptible individuals)
Treatment Options & Approaches
STANDARD APPLICATOR-GUIDED SUBDERMAL INSERTION (NEXPLANON/IMPLANON NXT PLATFORM): The current global standard uses the Nexplanon pre-loaded, disposable, modified applicator (MSD/Organon). The device is radio-opaque (contains barium sulphate) for X-ray, ultrasound, CT, and MRI localisation. The single-handed, trocar-based insertion technique deposits the rod at a depth of 3–5 mm below the skin surface in the subcutaneous plane of the medial upper arm. The entire procedure takes 60–90 seconds under local anaesthesia (1–2 mL of 1% lidocaine subcutaneously). No incision or suture is required. A pressure bandage is applied for 24 hours and a small adhesive dressing for 3–5 days. ULTRASOUND-GUIDED INSERTION (ENHANCED PRECISION PROTOCOL): For women with a BMI above 30 kg/m², very thin arms with minimal subcutaneous tissue, or significant procedural anxiety, real-time high-frequency (10–15 MHz) linear probe ultrasound guidance is used by experienced gynaecologists to precisely target the subdermal plane, confirm device trajectory, and immediately verify correct placement. This technique is now standard at tertiary gynaecology centres in India and the UAE and virtually eliminates the risk of deep muscular insertion. IMPLANT REMOVAL — STANDARD TECHNIQUE: Standard removal is performed under local anaesthesia via a 2–3 mm longitudinal incision over the palpable distal tip of the rod, followed by blunt dissection through the fibrous sheath that develops around the EVA matrix over time, and extraction with mosquito forceps. Procedure time: 5–15 minutes. A new implant can be inserted through the same incision site (simultaneous removal and replacement, or 're-do' procedure). IMPLANT REMOVAL — DEEP/NON-PALPABLE/IMPALPABLE IMPLANT TECHNIQUE: Approximately 1–2% of implants become non-palpable, most often due to deep (intramuscular or subfascial) insertion. Management follows a stepwise localisation protocol: 1. High-frequency ultrasound (first-line imaging) — identifies device position and depth relative to the biceps brachii muscle and neurovascular bundle. 2. MRI of the upper arm (second-line if ultrasound inconclusive) — superior soft tissue contrast to delineate implant in relation to vessels and nerves. 3. Fluoroscopy/X-ray — useful as Nexplanon is radio-opaque; confirms presence and gross location. 4. Surgical removal under ultrasound-guided real-time visualisation — performed in a minor operating theatre setting with a surgeon experienced in deep implant retrieval. In rare cases of intravascular migration (reported in < 0.03% of cases), cardiothoracic or vascular surgical involvement may be required. RE-INSERTION TIMING OPTIONS: • Immediate re-insertion (same visit, through same incision) • Delayed re-insertion (at next menstrual period or after pregnancy exclusion) EMERGING TECHNOLOGIES: Some centres in India and the UAE are piloting near-infrared (NIR) detection devices (e.g., SENSITEC detector systems) to aid non-palpable implant localisation in outpatient settings without radiation exposure, representing the next frontier in implant management.
Восстановление
STEP 1 — PRE-TRAVEL VIRTUAL CONSULTATION (1–2 weeks before travel): GAF Healthcare coordinates a teleconsultation with the receiving gynaecologist. The patient submits medical history, current medications, recent blood tests, and BMI. The clinician assigns WHO MEC category, confirms eligibility, and schedules the insertion appointment. The optimal timing within the menstrual cycle is planned (Days 1–5 preferred for immediate contraceptive cover; any day if pregnancy is excluded, with 7-day barrier contraception backup). STEP 2 — ARRIVAL AND DAY-OF-PROCEDURE ASSESSMENT (Day 1 in destination country): The patient attends the clinic or outpatient gynaecology department. A urine pregnancy test is performed. Vital signs and blood pressure are recorded. The procedure, risks, alternatives, and expected bleeding pattern changes are discussed using standardised counselling (FSRH/WHO framework). Written informed consent is obtained. STEP 3 — INSERTION PROCEDURE (Day 1, typically a 20–30 minute appointment): The patient lies supine with the non-dominant arm abducted and externally rotated (hand behind the head). The inner upper arm is cleaned with antiseptic. Local anaesthesia (1–2 mL lidocaine 1%) is infiltrated subdermally. The Nexplanon applicator is positioned at 0° (parallel to the long axis of the arm). The needle is advanced to its full length in the subcutaneous plane, the obturator is retracted, and the rod is deployed. Tactile confirmation is performed immediately — both clinician and patient should be able to palpate the rod. In high-BMI or complex cases, ultrasound confirmation is performed at the table. A pressure dressing and steri-strips are applied. The implant lot number and site are documented in the patient's health record and on a patient-held implant card. STEP 4 — IMMEDIATE POST-PROCEDURE OBSERVATION (30–60 minutes): The patient rests briefly in the recovery area. Bruising, arm tenderness, and normal expected side effects are reviewed. Analgesic advice (paracetamol or ibuprofen as required) is provided. The patient is given written aftercare instructions and the 24-hour GAF Healthcare patient support contact. STEP 5 — RECOVERY AND RETURN TO DAILY ACTIVITIES (Days 1–7): • Day 1–2: Mild bruising and tenderness at insertion site expected. Keep site dry for 24 hours; avoid heavy lifting with the affected arm for 48 hours. Pressure bandage removed after 24 hours; adhesive dressing retained for 3–5 days. • Day 2–3: Most patients feel completely normal. The implant is not visible but should be palpable as a small firm rod. • Day 7: Full return to all physical activities, including exercise and swimming. STEP 6 — FIT-TO-FLY CLEARANCE AND DEPARTURE (Day 1–2 post-insertion): There is no physiological contraindication to air travel after subdermal implant insertion. Most international patients fly home on the same day or the following day. GAF Healthcare provides a signed medical summary letter detailing the device type, lot number, insertion date, and removal date (3 years hence) for the patient to carry while travelling — essential for security screening transparency and future healthcare providers. STEP 7 — POST-RETURN FOLLOW-UP (Weeks 1–4 and Ongoing): • 1-week teleconsultation with the GAF Healthcare-coordinated gynaecologist to review any site concerns or unexpected bleeding patterns. • Ongoing virtual access to the treating clinician for 90 days post-procedure as part of GAF Healthcare's aftercare protocol. • 3-year implant lifespan: Patient is counselled on removal and replacement timing and advised to register the implant with their home-country gynaecologist.
Возможные риски
The subdermal contraceptive implant has an excellent safety profile, but patients should be counselled comprehensively on expected side effects and genuine risks prior to insertion. MENSTRUAL PATTERN CHANGES (most common reason for early removal — approximately 15–20% of users by 2 years): Irregular, unpredictable bleeding or spotting (most common, affecting up to 20% of users in the first year), infrequent bleeding (amenorrhoea in approximately 22%), prolonged or frequent bleeding (less common). Bleeding pattern in the first 3 months does not reliably predict future pattern. Persistent problematic bleeding can be managed with a short course of combined oestrogen-progestogen (if not contraindicated), mefenamic acid, or tranexamic acid. INSERTION-SITE COMPLICATIONS: Bruising (very common, resolves within 7–10 days), haematoma (uncommon, < 1%), infection at insertion site (rare, < 0.5% — managed with topical or oral antibiotics), paraesthesia or transient numbness of the medial cutaneous nerve of the forearm (rare if correct technique used), incomplete insertion (device failure to deploy — rare with modern applicator design). DEEP OR NON-PALPABLE INSERTION: Occurs in approximately 1–2% of cases, most commonly associated with incorrect insertion angle or high BMI. Requires ultrasound or MRI localisation and potentially surgical removal under image guidance. Choosing an experienced, trained inserter — as provided by GAF Healthcare's partner accredited facilities — is the single most important risk-mitigation factor. PROGESTOGEN-RELATED SYSTEMIC EFFECTS: Acne (new onset or worsening in up to 12%), mood changes or low mood (reported in a subset of users — women with a history of depression should be counselled specifically), headache, breast tenderness, decreased libido, weight gain (causality debated in studies; average weight change in RCTs is minimal). Ovarian follicular development is not fully suppressed — functional ovarian cysts (usually asymptomatic, self-resolving) occur in a proportion of users. ECTOPIC PREGNANCY RISK: Because the implant is so effective at preventing all pregnancy, the absolute risk of ectopic pregnancy is extremely low — lower than in non-contraceptive users. However, if pregnancy does occur during implant use (< 1 per 1,000 users over 3 years), the proportion that are ectopic is higher than in the general pregnant population. Any pregnancy symptoms in an implant user warrant urgent medical evaluation. FAILURE IN ENZYME-INDUCER USERS: Women on rifampicin, carbamazepine, phenytoin, topiramate, or St John's Wort should be counselled that hepatic enzyme induction may reduce ENG serum levels and contraceptive efficacy. An additional barrier method or switching to a copper IUD is recommended for these patients. VALIDATED RISK ASSESSMENT FRAMEWORK: All GAF Healthcare partner gynaecologists apply WHO Medical Eligibility Criteria (WHO MEC 2015, updated) and FSRH Clinical Guidance to pre-procedure risk stratification, ensuring that every patient receives a personalised risk-benefit assessment before device insertion.
Почему GAF Healthcare
GAF Healthcare provides comprehensive, end-to-end non-medical coordination for international patients travelling to India or the UAE for a contraceptive implant procedure — ensuring that what is already a straightforward outpatient procedure is also a completely stress-free travel experience. INDIA — VISA & ENTRY: Most nationalities travelling to India for medical treatment qualify for the Indian e-Medical Visa (e-MV), available online through the Indian government's official portal. GAF Healthcare's dedicated visa coordination team assists patients with the application, required documentation (GAF Healthcare letter of invitation from the treating hospital, passport-size photographs, travel itinerary), and expedited processing. The e-Medical Visa permits a stay of up to 60 days (triple-entry) and can typically be obtained within 3–5 business days. For a same-day or next-day-departure procedure, the short length of stay is well within e-MV parameters. UAE — VISA & ENTRY: Citizens of over 50 countries — including all EU/EEA states, the UK, the US, Australia, and Canada — receive a free visa on arrival in the UAE (Dubai/Abu Dhabi) valid for 30–90 days depending on nationality. For nationalities requiring advance visa arrangements, GAF Healthcare coordinates the UAE tourist or medical visa application process. The UAE's geographic position as a global aviation hub (Dubai International Airport is the world's busiest international airport) means that nearly all patients can reach Dubai or Abu Dhabi with direct or single-connection flights from virtually any origin city. AIRPORT TRANSFERS: GAF Healthcare arranges private, air-conditioned vehicle transfers between the international airport and the clinic/hotel in both India (partner hospitals in Delhi, Mumbai, Chennai, Bengaluru, Hyderabad) and the UAE (Dubai, Abu Dhabi). Transfer vehicles are booked to accommodate both the patient and any accompanying attendant. ACCOMMODATION: For patients who wish to stay overnight (optional for this outpatient procedure), GAF Healthcare has negotiated preferred rates at partner hotels ranging from comfortable 3-star guest houses to 5-star medical tourism-friendly hotels in proximity to partner hospitals. Rooms suitable for a patient and one attendant/companion are bookable through the GAF Healthcare patient portal. DEDICATED PATIENT COORDINATORS & TRANSLATION: Each patient is assigned a named GAF Healthcare Patient Coordinator who serves as a single point of contact from initial enquiry through post-procedure departure. For patients whose primary language is not English (or Hindi/Arabic in India/UAE respectively), certified medical interpreters are arranged — in-person or via video link — for the consultation and consent process. Languages commonly supported include Arabic, French, Russian, Swahili, Amharic, and Tagalog. MEDICAL DOCUMENTATION & CONTINUITY: GAF Healthcare ensures that every patient departs with a complete medical summary (procedure note, device details, lot number, next recommended removal/replacement date) formatted for easy handover to their home-country general practitioner or gynaecologist, supporting seamless continuity of care across borders. ACCREDITATION ASSURANCE: All GAF Healthcare partner facilities in India are NABH-accredited and/or JCI-accredited. Partner clinics and hospitals in the UAE hold JCI accreditation and/or are licensed and regulated by the Dubai Health Authority (DHA) or the Abu Dhabi Department of Health (DoH), guaranteeing international standards of clinical governance, infection control, and patient safety.
Частые вопросы о процедуре «Contraceptive Implant»
What is the cost of a contraceptive implant procedure in India versus the UAE?
How long do I need to stay in India or the UAE before I am fit to fly home after a contraceptive implant?
What is the success rate of the contraceptive implant, and how effective is it?
Похожие страницы
Как GAF Healthcare помогает выбрать лучшую больницу для «contraceptive implant» в Мумбаи, Индия
Найдите лучшие больницы для «contraceptive implant» в Мумбаи, Индия
На этой странице представлено 17 больниц в Мумбаи, Индия, чтобы вы могли сравнить аккредитацию и специализации в одном месте.
Поддержка, когда она нужна
Отправьте нам свои медицинские отчёты в WhatsApp или по email — наша медицинская команда изучит их и предложит больницу и план лечения.
Прозрачные, всё включено цены
Мы предоставляем единую детализированную смету, покрывающую расходы больницы и проживание — без скрытых платежей.
Организация визы, поездки и проживания
После выбора больницы мы помогаем оформить визовое приглашение, забронировать проживание рядом с больницей и организовать трансфер.
Хотите узнать примерную стоимость лечения? Используйте наш калькулятор стоимости для персональной оценки.
Частые вопросы о «Contraceptive Implant» в Мумбаи, Индия
Сколько больниц направления «Гинекология» представлено в Мумбаи, Индия?
Как вы выбираете больницы для списка?
Сколько стоит лечение в Мумбаи, Индия?
Следующий шаг
Отправьте нам свои медицинские отчёты — наша команда предложит больницу и план лечения для «Contraceptive Implant» в Мумбаи, Индия.
Свяжитесь с нами, если заметите неточность на этой странице.